Project Grant R21AA033213
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $578,234 on August 20, 2026, under the Alcohol Research Programs (CFDA 93.273) to establish a translational human laboratory model investigating alcohol's effects on pain in persons with co-occurring alcohol use disorder and chronic pain. The research uses a computer-controlled intravenous alcohol clamp to quantify alcohol's biphasic effects on pain perception—analgesia during the ascending phase and hyperalgesia...
- The National Institute on Alcohol Abuse and Alcoholism awarded the Regents of the University of Colorado, doing business as University of Colorado-Denver, $1,162,583 on September 10, 2025, under the Alcohol Research Programs (CFDA 93.273) to conduct research combining laboratory-based pain induction and ecological momentary assessment (EMA) methods to examine age-related differences in the relationship between alcohol use, pain, and inflammation. The research tests two hypotheses: that pain...
- The National Institute on Alcohol Abuse and Alcoholism awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $1,156,082 under the Alcohol Research Programs (CFDA 93.273) on September 25, 2025, to investigate the gut-brain axis and the role of butyrate in neuroinflammation and pain sensitivity. The research examines the relationship between alcohol use disorder, chronic pain, gut dysbiosis, and neuroinflammation, with focus on how gut microbial-derived short-chain...
- The National Institute on Alcohol Abuse and Alcoholism, under the Department of Health and Human Services National Institutes of Health, awarded the Regents of the University of Minnesota $400,585 on July 16, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the spinal mechanisms of alcohol-induced tactile hypersensitivity. The research addresses the relationship between chronic alcohol consumption and heightened pain sensitivity in individuals with alcohol use disorder. The...
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Pittsburgh $628,080 under the Alcohol Research Programs (CFDA 93.273) on May 1, 2026. This Project Grant (R01AA032487) funds a five-year investigation into whether a hyperactive nociceptin opioid peptide receptor (NOP) system drives relapse in heavy drinking alcohol use disorder (AUD) subjects, using positron emission tomography imaging with [11C]NOP-1A radiotracer and hydrocortisone challenge protocols. Prior...
- The National Institute on Alcohol Abuse and Alcoholism awarded Louisiana State University Health Sciences Center New Orleans $158,600 on November 3, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct research identifying the mechanisms underlying alcohol-induced hyperalgesia in adult rats. The project period runs through August 31, 2028, with work performed in New Orleans, Louisiana. The award funds experimental research examining how chronic adolescent alcohol exposure...
- The National Institute on Alcohol Abuse and Alcoholism awarded Trustees of Boston University $580,556 on May 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the role of pituitary adenylate cyclase activating polypeptide (PACAP) in heavy alcohol drinking and associated anxiety-like behavior. The recipient will conduct mechanistic research using animal models of heavy alcohol drinking combined with pharmacological, molecular, and viral approaches to test whether the...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $143,784 Project Grant (CFDA 93.273 - Alcohol Research Programs) to Louisiana State University Health Sciences Center New Orleans on July 30, 2024. The grant will support research to investigate the effects of adolescent opioid exposure on alcohol-induced hyperalgesia (increased pain sensitivity) in adult mice. The research aims to test the hypothesis that exposure to opioids during adolescence increases the magnitude of...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Ohio State University $226,406 on August 10, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate pain sensitivity, alcohol-induced analgesia, and heavy drinking in individuals with opioid use disorder. The research addresses a critical gap in understanding mechanisms that drive concurrent alcohol and opioid use, which occurs at rates 13 times higher in individuals with opioid use disorder compared to the...
- The National Institute on Alcohol Abuse and Alcoholism awarded Trustees of Tufts College $686,774 on July 20, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct behavioral neurobiology research on stress, alcohol responsivity, and alcohol drinking patterns. The research uses rodent models to investigate how stress exposure alters sensitivity to alcohol's aversive effects and the neural circuits involved. The study employs classical and operant conditioning paradigms combined with...
The National Institute on Alcohol Abuse and Alcoholism awarded Boston Children's Hospital $489,479 under Project Grant R21AA033213 on August 1, 2026, to characterize physical and emotional pain during protracted withdrawal from alcohol use disorder and identify predictive factors and brain-behavior mechanisms underlying these pain syndromes. The research addresses a gap in understanding how physical pain (musculoskeletal, phantom pain) and emotional pain (hyperkatifeia, stress, anhedonia, social isolation) that persist weeks to years after alcohol cessation drive relapse risk, despite remaining poorly studied and undefined under DSM-5 criteria. The recipient will conduct longitudinal studies to identify clinical and behavioral patterns during pre-abstinence and early post-abstinence stages that predict pain severity during protracted withdrawal, investigate maladaptive sensorimotor and reward circuitry in the supratentorial brain and cerebellum underlying these pain phenomena, and develop interdisciplinary biopsychosocial treatment strategies to prevent protracted withdrawal or enhance recovery. The award is structured as a Project Grant under the Alcohol Research Programs (CFDA 93.273), which supports fundamental knowledge development applicable to treatment improvement and prevention of alcoholism and alcohol-related problems. The period of performance runs from August 1, 2026, through July 31, 2028, with place of performance in Boston, Massachusetts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $489.5k | 8/3/26 |